1Miller K, Raabe N, Trachtenberg J, et al. ZD1839, an epidermal factor receptor tyrosine kinase inhibitor (EGFR-TKI) ,is well tolerated in combination with mitoxantrone and prednisone in patients with hormone-refactory cancer ( HRPC ) [ J ]. Proc ESMO,2002,91 :abstr 3270. 被引量：1
2Wu YL, Yang XN, Gu LJ. The characteristics of patients with nonsmall cell lung cancer with complete response treated with ZD1839[J]. Proc ASCO ,2003,22:2770a. 被引量：1
3Burris HA 3rd, Moore M J, Andersen J ,et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [ J ].Clin Oncol, 1997,15 ( 6 ) : 2403 - 2413. 被引量：1
4Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life- in non-small cell lung cancer : a review of the hterature and future directions[ J]. Clin Cancer Res, 1998,4~1087 - 1100. 被引量：1
5Dy GK, Adjei AA. Novel largets for lung cancer therapy[ M ]. Part 1. J Clin Oncol,2002,20:2881 -2894. 被引量：1
6Barton J,Blackledge G,Wakeling A. Growth factors and their receptors: nee, targets for prostate cancer therapy[J]. Urology,2001,58( 2 Suppl 1) : 114 - 122. 被引量：1
7Fubuoka M, Yano S, Graccone G, et al. Multi-institutional randomized phase Ⅱ trial of Gefitinib for previously treated patients with advanced non-small cell lung cancer[ J ]. Clin Oncolol,2003,21 ( 12 ) : 2237 - 2246. 被引量：1
8Ciardiello F, Caputo R, Bianco R ,et al. Inhibition of growth factor productioll and angiogenesis in human cancer cells by ZD1839 (Iressa) ,a selective epidermal growth factor receptor tyrosine kinase inhibitor[ J ]. Clin Cancer Res,2001,7 ( 5 ) : 1459 - 1465. 被引量：1
9Chan KC, Knox WF, Gandhi A, et al. Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation[J]. Br J Surg,2001,88(3) :412 -418. 被引量：1
10Sirotnak FM,Zakowski MF,Miller VA,et al. Efficacy of cytotoxic agents against human tumor xenografls is markedly enhanced by coadministration of ZD1839 ( Iressa), an inhibitor of EGFR tyrosine kinase[ J ]. Clin Cancer Res,2000,6 ( 12 ) :4885 - 4892. 被引量：1
4SALTZ LB, LENZ H J, KINDLER HL, et al. Randomized phase Ⅱ trialof cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study[J].J Clin Oncol, 2007,25 (29) : 4557-4561. 被引量：1
5LACOUTURE M E, BASTI S, PATEL J, et al. The SERIES Clinic: an interdisciplinary approach to the management of toxicities to EGFR inhibitors[J].Support Oncol, 2006,4(5) : 236-238. 被引量：1
6WOLLENBERG A, KROTH J, HAUSCHILD A, et al. Cutaneous side effects of EGFR inhibitors-appearance and management[J].Dtsch Med Wochenschr, 2010, 135 (4) : 149-154. 被引量：1
7LIPWORTH AD, ROBERT C, ZHU AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia) :focus on sorafenib and sunitinib[J]. Oncology, 2009,77 (5) : 257-271. 被引量：1
8KIM H, HONG M, SHIN SJ, et al. Sunitinib for unselected Korean patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles[J].Clin Oncol, 2011,80(5-6) : 395-405. 被引量：1
9WOOD L S. Management of vascular endothelial growth factor and muhikinase inhibitor side effects[J].Clin J Oncol Nurs, 2009,13 (Suppl) : 13-18. 被引量：1
10ZHOU A.Management of sunitinib adverse events in renal cell carcinoma patients : The Asian experience[J]. Asia-Pacific Journal of Clinical Oncology, 2012, 8: 132-144. 被引量：1
